Viking Therapeutics (VKTX) Projected to Release Earnings on Wednesday

Posted by Brenda Bartman on Oct 21st, 2026

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) will likely be posting its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:00 PM ET.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.11. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.58) EPS. On average, analysts expect Viking Therapeutics to post ($4.46) EPS for the current fiscal year and ($4.08) EPS for the next fiscal year.

Viking Therapeutics Price Performance

NASDAQ VKTX opened at $26.71 on Wednesday. The stock has a market capitalization of $3.37 billion, a PE ratio of -5.73 and a beta of 0.66. Viking Therapeutics has a 1 year low of $24.94 and a 1 year high of $43.15. The business’s 50-day moving average is $31.85 and its 200 day moving average is $32.96.

Insider Activity

In other news, CEO Brian Lian sold 148,517 shares of Viking Therapeutics stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $33.32, for a total transaction of $4,948,586.44. Following the sale, the chief executive officer owned 2,572,441 shares of the company’s stock, valued at approximately $85,713,734.12. The trade was a 5.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Greg Zante sold 21,217 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $33.47, for a total transaction of $710,132.99. Following the transaction, the chief financial officer owned 212,204 shares in the company, valued at $7,102,467.88. This represents a 9.09% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 187,951 shares of company stock valued at $6,268,442. Corporate insiders own 5.30% of the company’s stock.

Analyst Ratings Changes

VKTX has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Viking Therapeutics in a research report on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Thursday, October 15th. JPMorgan Chase & Co. reduced their target price on Viking Therapeutics from $75.00 to $65.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Morgan Stanley restated an “overweight” rating on shares of Viking Therapeutics in a report on Tuesday, September 22nd. Finally, UBS Group initiated coverage on Viking Therapeutics in a report on Wednesday, October 14th. They set a “buy” rating and a $94.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Viking Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $98.10.

View Our Latest Report on VKTX

About Viking Therapeutics

(Get Free Report)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company develops therapies for metabolic and endocrine disorders, with a focus on conditions involving obesity, nonalcoholic steatohepatitis (NASH), and other liver and lipid disorders.

Viking’s lead program is VK2735, an investigational dual GLP-1/GIP receptor agonist being developed in injectable and oral formulations for obesity and related metabolic conditions.